{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:27:53Z","timestamp":1790749673418,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion typically in the presence of other signs of intraocular inflammation (IOI). The purpose of this report is to provide guidance on the use of brolucizumab for neovascular age-related macular degeneration to a global audience.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A literature review was conducted on adverse events related to IOI after administration of brolucizumab in eyes with neovascular age-related macular degeneration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Possible risk factors for IOI and retinal vascular occlusion after brolucizumab should be considered before administering brolucizumab. Patients who receive brolucizumab should be educated on the symptoms, signs, and time course of IOI after brolucizumab. Before each injection of brolucizumab, physicians should assess the eye for any signs of inflammation and not treat with brolucizumab if inflammation is detected. Treatment of IOI should be prompt and provided with particular attention to the posterior segment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Careful patient selection, patient education, assessment for inflammation, and intensive treatment of possible inflammation are important when using brolucizumab in patients with neovascular age-related macular degeneration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003556","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T19:02:04Z","timestamp":1661194924000},"page":"1629-1637","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"42","author":[{"given":"Frank G.","family":"Holz","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Bonn, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","article-title":"Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting","volume":"38","author":"Boulanger-Scemama","year":"2015","journal-title":"J Fr Ophtalmol"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients","volume":"12","author":"Ehlken","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/OPTH.S92548","article-title":"Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey","volume":"9","author":"Varano","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and\/or vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s41433-020-01227-w","article-title":"Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.ajoc.2020.100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamaophthalmol.2020.2810","article-title":"Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity","volume":"138","author":"Kondapalli","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"100680","DOI":"10.1016\/j.ajoc.2020.100680","article-title":"Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"100989","DOI":"10.1016\/j.ajoc.2020.100989","article-title":"Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study","volume":"20","author":"Iyer","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/j.jcjo.2021.04.004","article-title":"Retinal vasculitis after intravitreal injection of brolucizumab","volume":"57","author":"Antaki","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10384-021-00819-7","article-title":"Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic","volume":"65","author":"Hikichi","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10384-021-00818-8","article-title":"Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy","volume":"65","author":"Kataoka","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","article-title":"Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study","volume":"259","author":"Maruko","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00347-021-01321-8","article-title":"[Intraocular inflammation with brolucizumab use: patient management-diagnosis-therapy]","volume":"118","author":"Holz","year":"2021","journal-title":"Ophthalmologe"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/s41433-020-01324-w","article-title":"Brolucizumab-foreseeable workflow in the current scenario","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.oret.2021.05.003","article-title":"Clinical characteristics and outcomes of eyes with intraocular inflammation after brolucizumab: post hoc analysis of HAWK and HARRIER","volume":"6","author":"Singer","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00347-021-01330-7","article-title":"Bilateral vasculitis following intravitreal brolucizumab injection(in German)","volume":"119","author":"Kessler","year":"2022","journal-title":"Ophthalmologe"},{"key":"R31-20250607","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00347-021-01323-6","article-title":"[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration]","volume":"119","author":"Riedel","year":"2022","journal-title":"Ophthalmologe"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2016.02.028","article-title":"Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept","volume":"165","author":"Rayess","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R34-20250607","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R35-20250607","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00347-020-01253-9","article-title":"[Vaso-occlusive retinitis following intravitreal injection of brolucizumab]","volume":"118","author":"Angerer","year":"2021","journal-title":"Ophthalmologe"},{"key":"R36-20250607","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early experience with brolucizumab treatment of neovascular age-related macular degeneration","volume":"139","author":"Enr\u00edquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R37-20250607","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00347-021-01343-2","article-title":"[Acute unilateral loss of vision after intravitreal injection of a VEGF inhibitor]","volume":"118","author":"Kaupke","year":"2021","journal-title":"Ophthalmologe"},{"key":"R38-20250607","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00347-021-01341-4","article-title":"[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]","volume":"119","author":"Leclaire","year":"2022","journal-title":"Ophthalmologe"},{"key":"R39-20250607","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/ijo.IJO_3436_20","article-title":"Immediate onset of sterile endophthalmitis with hypopyon after intravitreal brolucizumab in a case of polypoidal choroidal vasculopathy","volume":"69","author":"Narayanan","year":"2021","journal-title":"Indian J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:00:45Z","timestamp":1749319245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003556"}},"subtitle":["Patient Selection, Evaluation, and Treatment"],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003556","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}